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Abstract
Background: During pandemics, health authorities may be uncertain about the spread and severity of the disease
and the effectiveness and safety of available interventions. This was the case during the swine flu (H1N1) pandemic
of 2009–2010, and governments were forced to make decisions despite these uncertainties. While many countries
chose to implement wide scale vaccination programmes, few accomplished their vaccination goals. Many research
studies aiming to explore barriers and facilitators to vaccine uptake have been conducted in the aftermath of the
pandemic, including several qualitative studies.
Aims:
1. To explore public attitudes to the swine flu vaccine in different countries through a review of qualitative
primary studies.
2. To describe and discuss the implications drawn by the primary study authors.
Methods: Systematic review of qualitative research studies, using a broadly comparative cross case-study approach.
Study quality was appraised using an adaptation of the Critical Appraisal Skills Programme (CASP) quality
assessment tool.
Results: The review indicates that the public had varying opinions about disease risk and prevalence and had
concerns about vaccine safety. Most primary study authors concluded that participants were uninformed, and that
more information about the disease and the vaccine would have led to an increase in vaccine uptake. We find
these conclusions problematic. We suggest instead that people’s questions and concerns were legitimate given the
uncertainties of the situation at the time and the fact that the authorities did not have the necessary information to
convince the public. Our quality assessment of the included studies points to a lack of reflexivity and a lack of
information about study context. We suggest that these study weaknesses are tied to primary study authors’ lack of
acknowledgement of the uncertainties surrounding the disease and the vaccine.
Conclusion: While primary study authors suggest that authorities could increase vaccine uptake through increased
information, we suggest instead that health authorities should be more transparent in their information and
decision-making processes in future pandemic situations.
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Background
Over the last few decades, global and national govern-
ments have issued a number of warnings to the general
public about the outbreak of potentially dangerous dis-
eases. There has been widespread concern that these dis-
eases, including SARS and seasonal influenzas, could
cause serious harm to individuals and could pose a
threat to public health. However, there has also been un-
certainty regarding the spread and severity of these dis-
eases as well as the effectiveness and safety of available
preventive or curative interventions. When faced with
the possibility of widespread disease but with high de-
grees of uncertainty, governments need to make difficult
decisions about how to respond. In some cases, they
have chosen to deliver large-scale public health interven-
tions, such as vaccines. However, the success of these
strategies depends on public participation and support,
and members of the public also need to make their own
decisions while faced with the same uncertainties.
In this review, we synthesised existing studies of public
reactions to the so-called swine flu pandemic of 2009–
2010 and the vaccination strategies that were put in
place. By synthesising the results of primary studies that
have explored people’s attitudes to these strategies and
the implications that primary study authors have drawn
from these studies, we hoped to learn lessons that could
be useful for future pandemics.
The swine flu pandemic
In April 2009, the public was notified about the outbreak
of a new influenza virus in Mexico. During March and
April of that year, almost 2000 cases had been registered,
with initial reports indicating severe illness among young
and healthy people as well as high mortality rates [1, 2].
For instance, one report of patients that had been hospi-
talised with the virus observed that 6,5 % had become
critically ill and 41 % of these died [1]. The influenza,
which was popularly called “swine flu”, was caused by an
A (H1N1) virus that had not been known to cause infec-
tion in humans before. The virus was later officially
termed A(H1N1)pdm09 [3].
The disease proved to be as contagious as seasonal flu
and quickly spread through the Americas to Europe and
Asia. In June 2009 the World Health Organization
(WHO) declared a pandemic based on the criterion that
the transmission was intercontinental [1, 4]. However,
the severity of the disease was not part of the WHO’s
definition of a pandemic [1, 5]. In fact, at the time of de-
claring the pandemic, the WHO considered the severity
of swine flu to be comparable to seasonal flu, but with
the important exception that young healthy individuals
seemed to be more severely affected [1, 5–7]. Neverthe-
less, the WHO was concerned that the virus could mu-
tate and become more deadly, and was also aware that
morbidity rates might vary across social groups and
regions, as seen in previous pandemics.
The swine flu vaccine
The unpredictable nature of the pandemic encouraged
the WHO as well as regional and national health author-
ities to act quickly. National and supra-national pan-
demic preparedness plans and vaccine strategies were
activated shortly after the outbreak in Mexico, and the
WHO initiated a rapid process of vaccine development
once it had been established that the seasonal influenza
vaccine did not offer protection against the pandemic
virus. This vaccine was ready for use in September 2009,
after a development and production time of four and a
half months [1]. By comparison, the seasonal flu vaccine
is usually developed and produced on a large scale in six
months. The process used was otherwise similar. The
testing and authorizing process by the European Medi-
cines Agency (EMA) and the US Food and Drug Admin-
istration (FDA) was also accelerated [1, 4, 6, 8–14].
The speed of the vaccine development process gave lit-
tle time to assess the effectiveness and safety of the vac-
cine, and assumptions about vaccine effectiveness and
safety were largely based on efficacy and safety data from
the seasonal flu vaccines and from testing of mock-up
vaccines using another strain of flu virus [1, 8, 15]. Effi-
cacy and safety data from seasonal flu vaccines was gen-
erally regarded to be transferable to the H1N1 vaccine.
But while the different seasonal flu vaccines are used on
similar populations each year, including health care
workers and the elderly, the H1N1 vaccine was used on
a wider selection of the population, including small chil-
dren, for which there was little existing testing or phar-
macovigilance data. Representative data regarding the
effectiveness and safety of the new vaccine in its target
population groups was first collected through monitor-
ing as mass vaccination was being implemented. It then
became evident that the vaccine was more effective than
first assumed and that at least short-term adverse effects
were similar to those of the seasonal flu vaccines. In
2012, however, rare but serious long-term effects were
identified in several European countries, including an as-
sociation with narcolepsy in children and adolescents
vaccinated with some of the pandemic vaccines that
used a new type of oil-based adjuvant and a mercury-
containing preservative [15]. The exact relationship
between the vaccine and this chronic disorder has still
not been established.
National and international responses to the swine flu
pandemic
In July 2009, the WHO recommended that all countries
should begin by vaccinating their health workers. Coun-
tries were then advised to prioritise high-risk groups,
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including pregnant women, people with specific chronic
conditions, healthy young adults, healthy children, and
finally, older adults [16]. However, the WHO pointed
out that the vaccines had not yet been extensively evalu-
ated for their safety in certain population groups, and
underlined the importance of post-implementation sur-
veillance and rapid sharing of safety and effectiveness
studies. The WHO also made it clear that the recom-
mendations would need to be changed if and when new
evidence became available.
National health authorities responded differently to
the pandemic [1, 4, 5, 9, 17]. Most countries followed
the WHO’s recommendations regarding priority groups,
although there was some variation, for instance with re-
gard to whether vaccination was recommended for small
children [4]. Some wealthy countries offered vaccines to
the whole population while other countries only offered
vaccines to those defined as priority groups. This was
primarily because some countries did not have enough
vaccines for universal access, but was also because some
authorities deemed the severity of the disease as low or
because they were concerned about the safety of the vac-
cine [6, 17]. As it gradually became likely that the dis-
ease would not be as severe as first suspected, some
countries also changed their vaccination strategies [1, 6].
National health authorities also used different strategies
to distribute the vaccine, and bought different types of
vaccines; with or without adjuvants and with different
types of adjuvants and preservatives. Many European
countries, as well as Canada, used the oil-based adju-
vated vaccines, while for instance the USA used vaccines
with traditional, aluminium-based adjuvants [15]. Several
reports have pointed out that this cross-country vari-
ation in vaccination strategies was unfortunate as it
was difficult for national health authorities to explain
to the public why they apparently drew different con-
clusions from risk assessments regarding the pan-
demic and the vaccine than other comparable
countries [1, 6, 9, 17].
Public responses to the swine flu pandemic and to the
vaccine strategies
Regardless of the strategies they chose, most govern-
ments were dissatisfied with their vaccination rates, and
in 2010, only four out of 30 EU countries reported that
they had met their vaccination targets [6]. Since the pan-
demic, a number of survey-based studies have aimed to
identify factors that influenced people’s uptake of the
pandemic vaccine [18–34]. These surveys, as well as two
reviews of the surveys [23, 35] suggest that people bal-
anced what they knew about their risk of getting the dis-
ease with what they knew about the safety of the
vaccine, many deciding that swine flu was not severe
enough to accept a vaccine of unknown safety.
In addition to these quantitative surveys, a number of
qualitative studies have been carried out to understand
more about people’s knowledge, attitudes and behaviour
regarding the H1N1 pandemic and the vaccine. A deeper
understanding of people’s reactions to pandemics and to
public health recommendations can provide a good basis
for future policy decisions regarding public health
threats where there is much uncertainty. However, a sys-
tematic review of the qualitative studies has so far not
been conducted.
Objectives
We set out to synthesise the results of existing qualita-
tive studies with the primary aim of exploring attitudes
to the pandemic vaccine among the public in different
parts of the world and belonging to different target
groups. Our secondary aim was to describe and discuss





We included studies where the primary focus was the
experiences and attitudes of vaccine recipients or poten-
tial recipients regarding the H1N1 influenza vaccine de-
livered in connection with the 2009 pandemic.
Types of studies
We included studies that used qualitative study designs
including ethnographic research, case studies, and
process evaluations. We included these studies if they
had used qualitative methods for data collection, includ-
ing focus group interviews, individual interviews, obser-
vation and document analysis; and qualitative methods
for data analysis, including thematic analysis or any
other appropriate qualitative analysis method that en-
ables analysis of text and observations and narrative
presentation of findings.
Study exclusion criteria
We excluded the following types of studies:
 Studies where qualitative research methods had not
been used or where the qualitative data in a mixed
methods study were not presented separately
 Studies where the focus was on attitudes to vaccines
in general (i.e., not specifically the swine flu vaccine)
 Studies where data had been collected before 2009
 Studies where the study participants were not talking
about their own views (e.g., healthcare workers or
planners talking about the public’s attitudes)
 Studies where the full text was in a language we did
not master
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Data collection and analysis
Search methods for identification of studies
We searched the following databases for studies pub-
lished from April 2009 onwards:
– MEDLINE In-Process & Other Non-Indexed Citations,
MEDLINE Daily, MEDLINE and Ovid OLDMEDLINE
1946 to Present, OvidSP (searched 9th December
2013)
– CINAHL 1980 to present, EbscoHost (searched 16th
December 2013)
– EMBASE 1980 to 2013 Week 50, OvidSP (searched
16th December 2013)
– Psycinfo 1987 to Month 12 Week 51 2013 (searched
18th December 2013)
– Science Citation Index 1975 to present, Social
Sciences Citation Index 1975 to present, ISI Web of
Knowledge (Searched 18th December 2013)
We limited searches to English, Scandinavian lan-
guages and Spanish for feasibility reasons. See Additional
file 1 for search strategy.
Study selection procedure
One review author (BC) assessed the titles and abstracts
of the identified records and removed all records that
were clearly not relevant. Both review authors then inde-
pendently assessed the eligibility of the remaining
records. The full text of all the papers identified as po-
tentially relevant by one or both review authors were re-
trieved. These papers were then assessed independently
by both review authors. Disagreement between review
authors was resolved through discussion.
Analysis
We extracted data from each paper that was broadly
relevant to the objectives of the review, i.e., all data re-
lated to people’s experiences and views regarding the
disease, preventive measures (including the vaccine),
treatments, and information about swine flu. We also
extracted background information about the first au-
thor’s name, year of publication, the country where the
study took place, the study participants, when the study
took place and the aim of the study (See Table 1).
When analysing the data we used a broadly compara-
tive case study approach informed by tools and tech-
niques outlined in the narrative synthesis framework,
where each included study was considered a case [36].
In line with this approach, both review authors inde-
pendently read and reread the selected studies, and iden-
tified key themes, much as we do when analysing
interview transcripts or other types of documents in pri-
mary qualitative research. The review authors searched
for themes in all sections of the reports, including the
background, results and discussion sections until all the
studies were accounted for and no new themes were
identified. The review authors then discussed and agreed
upon the definitions and boundaries of each of the
emerging themes and then grouped them into broader
themes. These themes, in combination with a list of in-
cluded studies were used as the basis for a matrix derived
from an approach described by Miles and Huberman [37].
Both review authors then extracted and condensed the in-
formation from each study pertaining to the different
themes and inserted this information into the matrix. The
matrix also summarised key information about each study
(first author, date, country, study characteristics), and fa-
cilitated detailed comparison of each theme across the
studies, constituting the basis for our synthesis of findings
from the studies. By re-arranging the order of the studies
according to the different background characteristics, e.g.,
study country, type of participants, time of study, the re-
view authors were also able to check whether there were
any patterns in the findings related to these traits.
Assessment of methodological limitations in the included
studies
Both review authors independently applied a set of qual-
ity criteria to each included study. Any disagreements
between the two review authors were then resolved
through discussion. The review authors appraised the
studies using the main elements of the Critical Appraisal
Skills Programme (CASP) quality assessment tool for
qualitative studies [38], as in other syntheses of qualita-
tive evidence [39–41]. We did not exclude studies
because of low study quality.
The main assessment criteria extracted from CASP
were:
1. Is the study context clearly described?
2. Is the sampling method clearly described and
appropriate for the research question?
3. Is the method of data collection clearly described
and appropriate for the research question?
4. Is the method of data analysis clearly described and
appropriate for the research question
5. Is there evidence of researcher reflexivity?
6. Are the claims made supported by sufficient
evidence?
(For an overview of the quality assessment, see
Additional file 2.)
Results
Description of the included studies
Results of the search
We initially identified and assessed 1326 titles and ab-
stracts and considered 40 of these studies in full text.
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Table 1 Profile of the included studies
First author, year Where Who Data source When Authors’ aim




To explore motives, beliefs and reactions
of individuals with varying backgrounds
who did not get vaccinated.





To identify and analyse the factors related
to vaccine uptake and refusal





6 focus groups and 10 key
informant interviews
66 participants
June–August 2010 To explore knowledge, attitudes and
behaviours of low-income women;
improve communication in emergency
response. To identify factors that affect this
high priority group’s ability to successfully
comply with vaccination recommendations.





To explore and compare info needs, worries
and concerns, and health-related behaviours
regarding H1N1 in people with respiratory
conditions and their family members
Cassady, 2012 [46] USA
(California)




Summer 2010 To gather a better understanding of the
dynamics that limit flu and H1N1 vaccination
among hard-to-reach Latinos in California.
d’Alessandro, 2012
[45]
France Priority group (Cyctic fibrosis patients) Individual interviews
42 participants
June 2010 To analyse the reasons for refusal of H1N1
vaccination. Perceptions of vaccine, disease,
related risks in patients that declined and
accepted the vaccination





Focus on how First Nations and Metis people
in Manitoba, Canada, responded to the public
health management of pandemic H1N1
Henrich, 2012 [52] Canada General public Online comments to news articles
1,796 commentators
March 2009–May 2010 Despite efforts to promote vaccination, the
public’s intent to vaccinate remained low. In
order to better understand the public’s resistance
to getting vaccinated this study addressed factors
influencing the public’s decisions
Hidiroglu, 2010 [49] Turkey Priority group (Health care providers) Focus groups
33 participants
November 2009 To explore the factors that lead to resistance to
vaccination among a group of primary healthcare
workers in a district in Istanbul.
Hilton, 2010 [54] UK General public





To gain new insights into public understandings
of the role of key players in the pandemic and to
explore how people deciphered the threat and
perceived whether they could control the risks.
Lynch, 2012 [51] USA Priority group (Pregnant women) 18 focus groups
144 participants
September 2009 Presents findings from pregnant and recently
pregnant women regarding their perceptions
about the 2009 H1N1 and seasonal flu vaccines.
The paper further identifies needed info to
improve communication strategies to encourage
the H1N1 and seasonal flu vaccine and

















Table 1 Profile of the included studies (Continued)
Oria, 2011 [55] Kenya Priority group (Health care providers) 16 focus groups
113 participants
January 2010 To characterize health care providers








January–February 2010 To identify opinions of the general
population, risk groups and health care
providers of the 2009-repercussions.
Sim, 2011 [44] UK Priority group (Pregnant women) Individual interviews
10 participants
November 2009 To assess how pregnant Polish migrants
to Scotland weighed up the risks and
benefits of the V for pandemic H1N1 flu
in comparison with their Scottish
counterparts.
Siu, 2012 [56] China
(Hong
Kong)






To demonstrate the perceptions of patients
with chronic renal disease in Hong Kong
towards the new vaccine for H1N1, as well
as the main disincentives.




To explore people’s beliefs, perceptions,
reasoning, and emotional and contextual
factors that may influence responses to


















We assessed sixteen of the studies as fulfilling our in-
clusion criteria and included these in the review (See
Fig. 1-Flow chart).
Included studies-methods, setting, participants and
timeframe
Among the 16 included studies, seven gathered data
through focus group interviews, four used individual in-
terviews and four combined focus groups and individual
interviews, while one study analysed online comments
to news articles. Four studies were from the UK, three
from Canada, three from the USA and one from China
(Hong Kong), France, Kenya, Spain, Sweden and Turkey
respectively. Ten of the studies studied high risk or pri-
ority groups, including healthcare providers, pregnant
women and people with chronic respiratory conditions;
four studies studied the general public; and two studies
studied both priority groups and the general public. Two
studies focused on individuals that had chosen not to
get vaccinated, while the remaining studies included
people who had made different decisions. Most of the
data collection took place during the swine flu pandemic
from 2009 to 2010, and before the WHO declared that
the pandemic was over on August 10th 2010 [42].
(For an overview of the included studies see Table 1.)
Primary study authors’ aims and study premises
As specified in our inclusion criteria, all sixteen studies
explicitly aimed to explore the public’s views on the pan-
demic influenza vaccination. For most primary study
authors, achieving a better understanding of people’s
perceptions was seen as a means to the goal of increas-
ing public compliance with government vaccination
plans in the future, as illustrated by the following quote:
Researchers sought to identify the factors that affect
this high-priority population’s ability to successfully
comply with vaccination recommendations [43].:852
Primary study authors typically described swine flu as
an important threat to public health, stated that vaccin-
ation is the most effective method for preventing the
disease and related complications, and referred to na-
tional influenza vaccination coverage as insufficient.
Titles and abstracts assessed for 
eligibility by BC 
(n=1326) Titles and abstracts excluded by BC
Main reasons: Clearly quantitative  
methods, not focus on swine flu, not 
primary studies
(n=1242)
Titles and abstracts assessed for 
eligibility by BC and CG
(n=84)
Titles and abstracts excluded by BC 
and CG 
Main reasons: Not recipients’ 
attitudes, not qualitative, not 
empirical
(n=44)
Full text articles assessed for  
eligibility by BC and CG
(n=40)
Full text articles excluded by BC 
and CG 
Main reasons: Not qualitative data, 
full text in included language non- 
existent, not focus on swine flu, not 
recipients’ perspective
(n=24)Studies included in review 
(n=16)
Fig. 1 Flow chart. Overview over search and selection process leading to final sample of 16 included studies
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Main themes identified in the studies
We initially identified six themes. In this paper, we will
focus on three main themes that were discussed in all
the included studies and that were the most relevant to
our focus on people’s attitudes to vaccination. These
three themes were also most relevant to the main aim of
the primary studies; to explore how vaccination goals
could be achieved in future epidemics. These three
themes are people’s perceptions of the disease’s severity
and spread, their perceptions of the vaccine, and their
perceptions of health authorities’ information and vac-
cination strategies.
The additional three themes that will not be discussed
here included people’s perceptions of the information
they received from the media; their perceptions of the
information they received from health professionals; and
organizational or practical barriers and facilitators to
vaccination.
People’s perceptions of disease severity and spread
Some participants questioned the extent to which the
H1N1 virus really represented a pandemic or a “true
emergency”, referring to the fact that their own personal
experiences did not confirm this impression with regard
to either severity or spread [44–46]. Most participants
regarded the disease as relatively mild and as similar to
other types of influenza [47–52], felt that the danger or
risk was exaggerated, and did not take the government’s
urgent messages seriously [44–50, 52–55]. However,
others saw the disease as more severe [54, 55] or poten-
tially serious and sometimes deadly [43, 52, 53], and re-
ferred to the relatively high risk to young people [43, 52].
In some studies, people perceived their personal risk
of getting the disease as low [47, 53], while participants
in other studies saw this risk as high [49] or this percep-
tion varied between participants [45, 51]. People’s per-
ceptions about personal risk appeared to be based on
assumptions about the disease itself and the extent to
which it was contagious [47]; their own pre-existing
health conditions [44, 51, 53, 54]; their age [53]; or the
extent to which they knew of other people in their envir-
onment who had the disease [53, 55]. Some of the studies
specifically described or discussed how these different per-
ceptions regarding disease spread and severity or personal
risk influenced people’s decisions to take the H1N1 vac-
cine [43–47, 51, 53, 56].
People’s perceptions of the vaccine
Study participants were particularly concerned about the
vaccine’s potential side-effects. Some of this concern
reflected a scepticism to vaccines in general [47, 56], but
was in large part tied to concerns around the novelty of
this particular vaccine and the speed in which it had
been developed and approved [44, 45, 47–51, 54, 56].
Participants were concerned that the vaccine had not
been sufficiently tested [43, 45, 47, 48, 52–54, 57]. In
some studies participants noted that that the vaccine was
in fact being tested on the public [49, 55], describing them-
selves as “lab rats” [46] or “guinea pigs” [44, 45, 52, 58].
Participants with serious health conditions were con-
cerned that the vaccine would impact on these condi-
tions or interact with other medications [50, 56].
Pregnant women pointed out that the use of the vaccine
during pregnancy contradicted usual advice to avoid
medication during pregnancy [44, 54]. For this group,
the lack of data about potential side effects to the foetus
was of particular concern [44, 51, 54]. In other studies,
participants referred to a lack of information about the
vaccine components [55], or they were concerned about
specific components such as the adjuvants used in some
of the pandemic vaccines [45, 52]. While there was most
concern about the vaccine’s potential side-effects, partic-
ipants in some studies also raised concerns about the
vaccine’s effectiveness [43, 45, 47–49, 55].
Participants who had decided not to get vaccinated
generally believed they had made the right decision [47].
One study underlined that there were no signs that
those who chose not to get vaccinated had failed to
understand the official messages [44].
People’s perceptions of health authorities’ information and
vaccination strategies
In general, study participants reported that they had re-
ceived inconsistent or even contradictory information
from different information sources or at different points
in time. This led to confusion and made some people
doubt the information [43–45, 47, 49, 51, 53, 56, 57].
Pregnant women also experienced a contradiction be-
tween advice from health authorities to be cautious with
medicines and their advice to accept the poorly tested
pandemic vaccine [44].
Participants with unanswered questions would have
liked one trusted official source of information and
would have preferred to receive more information dir-
ectly from the health authorities [43, 51, 57]. In some
studies where priority groups were interviewed, partici-
pants wanted targeted information and a specialised
information channel [50, 57].
Trust in health authorities and support for their vac-
cination strategies appeared to vary across study coun-
tries. UK participants typically saw the health authorities
as a key information source that they generally trusted.
Some of these participants stated that the pandemic had
not been overhyped by the government given its poten-
tial impact and that the authorities had handled the situ-
ation well. Participants here found it reassuring that the
government ordered enough vaccines and also that they
decided not to use them after all [44, 50, 54]. Some
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participants even recognised the government’s dilemma,
stating that they were “damned if they do and damned if
they don’t” offer the vaccine to the population [54]. In
Kenya, participants also felt that national health author-
ities offered clear and trustworthy information, although
they did not trust international health organisations such
as the WHO [55].
In Canada, participants conveyed less trust in health
authorities and in two of the three studies, participants
described health authorities as incompetent, accusing
them of taking too little and wrong action [52, 58]. Some
also thought that the authorities’ vaccination strategy
was politically motivated and that they focused on min-
imizing absenteeism or had given in to pressure from
the pharmaceutical industry instead of focusing on bene-
fits to the public.
In the study from Hong Kong, people voiced a general
distrust in health authorities which appeared to have im-
pacted on people’s perception of vaccine safety. One par-
ticipant believed that the government had continued to
promote vaccination once the vaccines had been bought
to avoid losing face and being blamed by the public for
wasting taxpayers’ money [56].
In some studies from the USA, Kenya, Turkey, Spain,
Canada and Sweden, a few participants were reported to
believe in rumours or “conspiracy theories”. This in-
cluded theories that the use of the vaccine was driven by
the economic interests of the pharmaceutical industry
[47, 52, 57], that the virus had been produced
intentionally to bring economic benefits to this industry
[49]; or that it was being used to distract people from
the economic recession or to defame Mexican people
[46]. A few had heard that the vaccine itself could cause
the influenza [43] while others were suspicious about
the motives behind their status as a priority group [58].
Primary study authors’ conclusions and advice to
authorities
As described earlier, the motivation of all of the primary
study authors was to explore people’s perceptions of the
swine flu vaccine. For most of the primary study authors
this was presented as a means to the goal of increasing
vaccine compliance, and all of the authors discussed the
implications that health authorities could draw from the
data to support this goal.
Increased compliance through better information and
communication strategies
Based on their findings that people had doubts about
the prevalence and seriousness of the disease as well as
concerns about the potential side effects of the vaccine,
several of the primary study authors concluded that the
public was confused [50, 51, 54, 57] and misinformed
[46, 51, 53]. Thus the main implication that most
primary study authors drew from their findings was the
need for better information or communication strategies
[43, 45, 46, 48–51, 53–57], the underlying assumption
being that a lack of appropriate information was the
main barrier to vaccine uptake:
- the confusion over the potential severity of H1N1
infection in pregnant women and its relationship to
seasonal flu needs to be considered. (…) Patients’
concern, confusion and lack of knowledge regarding
H1N1 and their willingness to change initial views
highlight a critical role for education [51].: p1662–3).
Some primary study authors encouraged health au-
thorities to provide information about the seriousness of
the disease and the need for the vaccine [49], about the
reason why specific groups were targeted [58] and about
the vaccine’s safety and effectiveness [43–45, 48, 49, 55,
56]. Typically, primary study authors underlined the
need to address people’s varying concerns regarding the
safety of the vaccine, implying that the provision of such
information would lead to increased vaccine compliance:
Constructing advice messages that address people’s
beliefs and concerns is also likely to be important to
persuade and empower people to adopt recommended
behaviours in a pandemic [48]:p 414)
Primary study authors also offered recommendations
regarding how information about the disease and the
vaccine should be communicated, for instance emphasis-
ing the importance of presenting the information clearly
[45] and in plain language [50], or encouraging the au-
thorities to offer information that was detailed [56] and
evidence-based [49]. One study emphasised the need for
the information to be consistent, although recognising
that it may be particularly difficult to offer consistent in-
formation during a pandemic “where the situation is
constantly changing and being reviewed” ( [50]:p41).
Several primary study authors also stressed that infor-
mation should be delivered by what was perceived by
the public to be “trustworthy”, “trusted” or “credible”
sources [45, 46, 50, 51, 55, 58]. One study that recog-
nized the importance of trust in health authorities, did
not discuss how to achieve this, simply advising the au-
thorities to improve “the public’s perception of govern-
ment trustworthiness and competence” ( [52]: p11).
Another study voiced the need to help people decide
which information to trust [50].
While most authors focused on information provision
as a key solution to low uptake, a few authors also
underlined the need to involve people in the decision
making process [47, 49]). The concept of “informed
choice” was referred to by one team of authors [53],
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while other authors advised health authorities to involve
the public, for instance through community-based dia-
logues about the vaccination campaign [49, 58], and to
“address the recipients’ perspective” [48, 54]. Authors
appeared to view public participation, informed choice,
and the use of evidence-based information as a means to
increase vaccine uptake rather than a means to encour-
age patient choice:
By eliciting and addressing the perspectives of
recipients of pandemic flu advice (…) future
government recommendations could enable people to
make choices that reduce the impact of a pandemic on
themselves and society [48]:p417).
As described above, many primary study authors
regarded participants as uninformed and focused on the
need to provide the public with more information and
consistent messages. Very few problematized this issue
[44, 58], for instance by discussing what this additional
information would contain and how this information
could be made clear and consistent given the uncertainty
surrounding both the disease and the vaccine. One
study, however, differed significantly from the others. In
their study of pregnant women in the UK, Sim et al.
argue that their participants had not misunderstood the
information from health authorities, but had in fact
internalised the rationale used in previous public health
messages, particularly in connection with the MMR vac-
cine. For MMR, the public had been reassured of the
safety of the vaccine by referring to the existence of ro-
bust clinical trials with long-term follow-up. “It was
exactly this type of scientific reasoning that women drew
on in highlighting what they perceived as the absence of
such information on the H1N1 vaccine, and their conse-
quent uncertainty about whether or not to accept it”
[44]:510. These study authors argued that health author-
ities in future situations should be open and transparent
about uncertainty:
Explicitly addressing uncertainty and acknowledging
areas where there has been no opportunity to
accumulate evidence may serve to enhance rather
than diminish the credibility of face-to-face or pub-
lished material which enables informed choice as the
influenza vaccine is offered routinely to pregnant
women in the UK provides a potential opportunity to
address these wider and more challenging issues in the
development of health information [44].: p510)
Quality appraisal of the included studies
All of the studies gave some description of the strategies
they had used to select participants and to collect and
analyse data. Although these descriptions tended to be
brief, we assessed these strategies as appropriate to the
research question.
However, two other elements of the quality assessment
gave us reason for concern. First, there was a lack of
contextual information in almost all of the studies, par-
ticularly regarding the type of information that the au-
thorities, the public in general, and study participants in
particular had access to during the pandemic. Exceptions
to this were seen in three studies where primary study
authors described the type and quality of information
available to the public through the media [44, 50, 54,
58]. Secondly, there was no evidence of researcher re-
flexivity in any of the studies. Reflexivity is perceived as
an integral process in qualitative research and requires
that researchers reflect upon their own background and
position, and how it will affect “what they choose to in-
vestigate, the angle of investigation, the methods judged
most adequate for this purpose, the findings considered
most appropriate, and the framing and communication
of conclusions” [58]:p483–4. This can entail, for in-
stance, reflecting on how the researcher’s status and role
may have influenced what the informants disclose and
how it is presented to the researcher [59]. We found no
explicit discussion of the primary study authors’ back-
ground or position, including how their studies might
have been influenced by these factors, nor were there
any information about their knowledge or opinions of is-
sues such as the pandemic, the vaccine, or the role of
the individual decision maker when faced with potential
public health crises.
These two weaknesses led us to question a third elem-
ent in the quality assessment, that is, the extent to which
the claims made by the study authors were sufficiently
supported by the evidence. We will return to these
issues in our discussion below.
Discussion
The studies that we identified in our review describe
how people had varying perceptions about the disease
and the vaccine, but were often uncertain about the se-
verity of the disease, the spread of the disease, and any
risks tied to the vaccine. People who chose not to be
vaccinated usually perceived their individual risk of get-
ting the disease as low, believed that they would not get
very sick from it, or were concerned that the vaccine
could lead to side effects. These findings are very similar
to findings from a number of quantitative surveys, re-
views and official evaluation reports [1, 6, 17, 18, 20–23,
25, 30, 31, 33, 34, 59].
Did primary study authors draw the right conclusions?
Most of the primary study authors concluded that partici-
pants were uninformed, and that more information about
disease severity and vaccine safety and effectiveness would
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lead to an increase in vaccine uptake. We find this conclu-
sion problematic. Most primary study authors offered very
little contextual information about what evidence regard-
ing the pandemic and the vaccine that was available to au-
thorities and to members of the public, or about the
certainty of this evidence. Solely based on the included pa-
pers, we were therefore unable to properly assess primary
study authors’ claims that the uncertainties participants de-
scribed often were a result of poor information. We thus
tried, through other sources (including the research litera-
ture, official reports and websites referred to in our back-
ground chapter), to get a better picture of the knowledge
authorities had at the time, as well as the information that
was available to the public during the pandemic. This in-
formation suggests that while some participants probably
did miss or misunderstand information, most of the uncer-
tainties described by study participants reflect those held
by health authorities and scientific environments at the
time, both with regard to disease severity, disease spread,
and potential vaccine side-effects. In fact, one might even
suggest that participants’ concerns were a rational response
to the information they received from the authorities ra-
ther than the result of a lack of information. With the ex-
ception of Sim et al. [44], and to a lesser degree Caress et
al. [50], none of the primary study authors discussed the
fact that the authorities were also uncertain about disease
spread and severity or vaccine benefits and harms, particu-
larly for certain parts of the population.
Health authorities have different decision making roles
than individuals. While health authorities are responsible
for the well-being of the public as a whole, individuals
are concerned with their own health and the health of
their families. But despite these differences, during the
swine flu, national authorities found themselves in a
similar position to that of the study participants as both
groups were faced with the dilemma of choosing action
or inaction without knowing the full implications of
either choice. This comparison was not made by most
primary study authors. Instead, the authors focus on the
authorities’ decisions to implement vaccination pro-
grammes, making little or no reference to the processes
and assessments of uncertainty leading up to these deci-
sions. Primary study authors appear to assume that the
vaccine was effective and safe and that the pandemic
represented a serious threat, something that neither the
public, the primary study authors, nor the authorities
could know with confidence at that time.
We regard this lack of information about and reflec-
tion on the context of the studies as a weakness in the
studies and connect it to a lack of researcher reflexivity
demonstrated by the primary study authors. The au-
thors’ contact information indicates that the majority of
them held positions at medical faculties and that some
of them were Ministry of Health employees. This
suggests that they have approached their own study with
a public health perspective, focusing on the achievement
of herd immunity through patient compliance. The pri-
mary study authors’ aim of increasing vaccine compli-
ance appears to have influenced their recommendations
that the public should be given more information and
more consistent information, while ignoring any uncer-
tainties this information might contain. Although a few
authors do refer to concepts such as shared decision-
making, informed choice and public involvement, they
do not discuss the potential tension between these
approaches and their goal of increasing vaccine compli-
ance, illustrated by one primary study author’s contra-
dictory statement that the public should be both
“empowered and persuaded” [48]. The uncertainty which
is a typical feature of pandemic vaccine development
[15, 60] can increase this tension between public and in-
dividual interests. When faced with a potential public
health crisis and under pressure to act quickly, author-
ities are probably far less inclined to highlight uncertain-
ties or to practice a transparent decision-making process
for fear that this will slow down or prevent vaccine up-
take, and the tension between public health goals and
the goals of the individual and of shared decision making
can therefore be intensified. At the same time, members
of the public are also likely to be more skeptical to the
safety of vaccines that have been developed, approved
and distributed by authorities in haste.
What other conclusions could the primary study authors
have drawn?
An alternative conclusion that primary study authors
might have drawn, and that we think would have been
more in line with their own findings, would have been
to recommend more transparency regarding uncertainty
as a strategy for increasing public trust in health author-
ities and thereby compliance with public health strategies.
One of the included studies do advocate transparency
from health authorities in situations of uncertainty [44].
This study is in line with several research reports that
argue for transparency in public health crises of “radical
uncertainty”, such as pandemics [60, 61]. In the after-
math of this pandemic, health authorities were criticised
for a lack of transparency with regard to decision mak-
ing processes and the evidence base for these decisions
[6, 60, 62–64]. A report evaluating the WHO’s perform-
ance during the pandemic also advises the WHO and
other health authorities to practice transparency in
future pandemic situations [1].
There are a number of reasons why transparency in the
face of uncertainty might be a sensible strategy [60, 61].
First of all, openness regarding core public health objec-
tives, such as herd immunity, may lead to an acknow-
ledgement and acceptance of these aims among the
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public. Also, in situations where people suspect uncertain-
ties regarding the spread or severity of the disease or the
safety and effectiveness of vaccines, authorities’ openness
about levels of uncertainty may help address conspiracy
theories. This would be difficult in situations where uncer-
tainty is downplayed. Another reason is that initial
assumptions may turn out to be wrong. In this case, the
pandemic was less dangerous than first feared, and the
vaccine is now associated with rare but serious side-
effects. If health authorities downplay uncertainties, it
becomes hard to explain any changes in government
strategies when new knowledge emerge and this can
potentially undermine the public’s willingness to trust
information from health authorities in the future. Accord-
ing to an EU report evaluating authorities’ management of
the swine flu, transparency “about what is not known is
just as important to the promotion of public trust as
transparency about what is known. Trust requires honest,
open and two-way communication” ( [61]: p615).
The UK studies in this review suggest that the public
can handle the knowledge that health authorities make
decisions in the face of uncertainties and that these deci-
sions may be wrong. Here, study participants reported
more positive attitudes to the government’s handling of
the pandemic than most others, and found it reassuring
that the government ordered enough vaccines but de-
cided not to use them after all [44, 50, 54], suggesting
that the acknowledgement of uncertainty and changes in
strategy are not necessarily perceived negatively by
members of the public.
While changes in strategy appeared to be acceptable to
at least some participants, participants in several studies
called for consistent information. The importance of
consistency was also emphasised in recommendations
made by several primary study authors and is supported by
a European Commission report on the EU-wide pandemic
vaccine strategies [65]. Here, the European Commission
concludes that health authorities should strive to report
consistent health messages across countries “to ensure citi-
zens do not receive mixed or wrong messages depending
on the area they are in” ( [65]:p51). But is it possible to be
transparent about uncertainties while also offering infor-
mation that is consistent? An independent review of the
UK pandemic response concludes that health authorities
managed to deliver a comprehensive information campaign
which combined the need for clarity and a “single authori-
tative voice” with recognition of and continuous updating
on the uncertainty of the disease ( [59]:p134). In this ap-
proach, consistency is achieved by ensuring that all of the
population receives the same message from the same
source, while uncertainty and the fact that information can
change over time is acknowledged. In other words, infor-
mation needs to be consistent at any given time, but this
does not imply that it cannot change over time.
The success of a transparent approach in these types
of situations is likely to depend on the relationship be-
tween the authorities and the public more generally. In
addition, studies of shared decision making in primary
health care suggest that members of the public may not
always want to make health care decisions on their own
or to share the responsibility for a decision if it turns
out to have negative implications [66–68].
But while transparency is not unproblematic, keeping
information from the public may not be an option in
most societies. An increasing number of people have ac-
cess to a broad spectre of information across borders.
The public can be expected to find out about inconsist-
ent policies across countries or about scientific uncer-
tainty, or worse, may be misguided by speculations and
rumours. Attempts from authorities to hide uncertain-
ties may thereby boost distrust and conspiracy theories.
It is therefore hard to think of any better strategy than
for governments to be transparent about clinical and
political processes as well as the reasons behind national
strategies.
Strengths and limitations of the review
Obviously, our own backgrounds and positions have in-
fluenced our interpretations of the studies, and this may
in different ways have led us to focus more than the pri-
mary study authors on the uncertainties faced by the au-
thorities surrounding the pandemic and the vaccine.
While we are both social scientists without expert know-
ledge about the pandemic or the vaccine, we had the ad-
vantage of hindsight regarding the actual prevalence of
the pandemic and the longer-term effects of the vaccine.
This may have made it easier for us to question the know-
ledge that was available to health authorities at the time.
Our synthesis of existing studies gave us access to data
from a large number of participants and several different
countries. The review showed that there were both com-
monalities and variations in people’s attitudes to the
swine flu vaccine and allowed us to look for patterns in
this variation by rearranging the matrix according to
characteristics of the study or the participants. The only
consistent pattern we discovered, however, was a vari-
ation across countries regarding people’s views of gov-
ernment information and strategies, as described above.
While these differences are interesting the range of study
countries in the review and the number of studies from
each country is too small and the reasons behind varia-
tions in people’s trust in their national government too
complex to draw robust conclusions about the registered
differences. Thus, it appears that a main limitation of
this review is the small number and skewed range of
study countries. Most of the studies were from Western
countries and from countries with democratic govern-
ments, there were no studies from Latin America (where
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the pandemic originated), and few were from low in-
come countries.
It is possible that people’s views about the information
they receive from health authorities are influenced by
the form of government in their country, while people’s
understanding of disease and of disease prevention and
treatment is likely to be influenced by their level of educa-
tion. For instance, people in some countries may be more
likely to trust authorities and comply with vaccination ad-
vice without doubting or questioning the rationale behind
it. Our suggestion that transparency about uncertainty in
pandemics is a necessary and inevitable strategy may
therefore not be transferable to every national context.
Conclusion
While the authors of the primary studies included in this
review suggest that national health authorities could in-
crease vaccine uptake through increased and more con-
sistent information, we suggest instead that health
authorities should be more transparent in their informa-
tion and decision-making processes in future pandemic
situations.
In the future, researchers should offer more information
about study context and pay more attention to issues of
reflexivity to ensure the relevance, trustworthiness and
usefulness of their advice for policy makers and others.
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